4576 D.Western Therapeutics Institute, Inc.デ・ウエスタン・セラピテクス研究所TSE Growth / Pharmaceuticals
0 posts
D.Western Therapeutics Institute, Inc. (4576) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
D.Western Therapeutics Institute, Inc. (4576) Stock Price HistoryNear an all-time low
D.Western Therapeutics Institute, Inc. closed at ¥45.0 on Nov 20, 2026, −30.8% over 1 month, −53.6% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥69,231 today (−30.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved −30.8%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥45.0 | −3 | −6.25% |
| Nov 19 (Thu) | ¥48.0 | +1 | +2.13% |
| Nov 18 (Wed) | ¥47.0 | −1 | −2.08% |
| Nov 17 (Tue) | ¥48.0 | +1 | +2.13% |
| Nov 16 (Mon) | ¥47.0 | −3 | −6.00% |
| Nov 13 (Fri) | ¥50.0 | +1 | +2.04% |
| Nov 12 (Thu) | ¥49.0 | −2 | −3.92% |
| Nov 11 (Wed) | ¥51.0 | +1 | +2.00% |
| Nov 10 (Tue) | ¥50.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥50.0 | −4 | −7.41% |
If you had invested ¥100,000 3 months ago, it would be worth ¥51,136 today (−48.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved −48.9%.
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥45.0 | −3 | −6.25% |
| Nov 19 (Thu) | ¥48.0 | +1 | +2.13% |
| Nov 18 (Wed) | ¥47.0 | −1 | −2.08% |
| Nov 17 (Tue) | ¥48.0 | +1 | +2.13% |
| Nov 16 (Mon) | ¥47.0 | −3 | −6.00% |
| Nov 13 (Fri) | ¥50.0 | +1 | +2.04% |
| Nov 12 (Thu) | ¥49.0 | −2 | −3.92% |
| Nov 11 (Wed) | ¥51.0 | +1 | +2.00% |
| Nov 10 (Tue) | ¥50.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥50.0 | −4 | −7.41% |
If you had invested ¥100,000 6 months ago, it would be worth ¥57,692 today (−42.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −5.6%, while this stock moved −42.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥45.0 | −23.7% |
| Oct 2026 | ¥59.0 | −23.4% |
| Sep 2026 | ¥77.0 | −13.5% |
| Aug 2026 | ¥89.0 | +17.1% |
| Jul 2026 | ¥76.0 | +2.7% |
| Jun 2026 | ¥74.0 | −2.6% |
| May 2026 | ¥76.0 | −15.6% |
If you had invested ¥100,000 1 year ago, it would be worth ¥46,392 today (−53.6%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −53.6%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥45.0 | −23.7% |
| Oct 2026 | ¥59.0 | −23.4% |
| Sep 2026 | ¥77.0 | −13.5% |
| Aug 2026 | ¥89.0 | +17.1% |
| Jul 2026 | ¥76.0 | +2.7% |
| Jun 2026 | ¥74.0 | −2.6% |
| May 2026 | ¥76.0 | −15.6% |
| Apr 2026 | ¥90.0 | −2.2% |
| Mar 2026 | ¥92.0 | −11.5% |
| Feb 2026 | ¥104 | +2.0% |
| Jan 2026 | ¥102 | +6.3% |
| Dec 2025 | ¥96.0 | −10.3% |
| Nov 2025 | ¥107 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥27,439 today (−72.6%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −72.6%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥45.0 | −53.1% |
| 2025 | ¥96.0 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥15,901 today (−84.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −84.1%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥45.0 | −53.1% |
| 2025 | ¥96.0 | ― |
If you had invested ¥100,000 in Nov 2009, it would be worth ¥21,635 today (−78.4%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +435.1%, while this stock moved −78.4%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥45.0 | −53.1% |
| 2025 | ¥96.0 | −52.2% |
| 2024 | ¥201 | +42.6% |
| 2023 | ¥141 | −46.2% |
| 2022 | ¥262 | +21.3% |
| 2021 | ¥216 | −25.3% |
| 2020 | ¥289 | −55.5% |
| 2019 | ¥649 | +13.1% |
| 2018 | ¥574 | +12.1% |
| 2017 | ¥512 | +25.5% |
| 2016 | ¥408 | −26.5% |
| 2015 | ¥555 | −47.4% |
| 2014 | ¥1,055 | +17.5% |
| 2013 | ¥898 | +596.1% |
| 2012 | ¥129 | +13.2% |
| 2011 | ¥114 | −18.0% |
| 2010 | ¥139 | −34.1% |
| 2009 | ¥211 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Nov 2009). Please check the latest prices before trading.
D.Western Therapeutics Institute, Inc. (4576) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of D.Western Therapeutics Institute, Inc. (4576)
Business overview
Together with consolidated subsidiary 「日本革新創薬」 (JIT), the company runs a drug discovery business that researches and develops pharmaceuticals centered on protein kinase inhibitors and earns revenue by licensing out its development candidates to pharmaceutical companies and others. In drug development, costs rise sharply as development moves from non-clinical to clinical trials, and a clinical development organization of a certain size becomes necessary. The company licenses out candidates at a relatively early stage, letting pharmaceutical companies strong in clinical development carry development forward, which keeps its own structure low-cost. It attributes its ability to license out early to its own technical strength in basic research and the efficient R&D that makes use of it. Revenue mainly consists of upfront payments at licensing, milestone payments at each development stage and royalties based on sales after launch.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 2.09x | Above the sector median of 1.86x (No. 44 from the lowest) |
|---|---|---|
| ROE | -68.61% | No. 49 in the sector (highest first); median 4.17% |
| Market cap | ¥2.6 bn | No. 74 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥107 | 2025/12/4 |
|---|---|---|
| 52-week low | ¥45 | 11/20 |
| Current position | 0.0% | Where the low is 0% and the high is 100% (close on 11/20: ¥45) |
| Year to date | -53.1% | No. 69 of 77 in the sector (best first) |
| 1 year | -53.6% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 1 times | Latest: 9/29 (No. 29) |
|---|---|---|
| Top 50 losers | 1 times | Latest: 11/4 (No. 50) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/12 15:302026年12月期 第3四半期決算短信〔日本基準〕(連結)
- 11/12 15:30営業外収益及び営業外費用の計上に関するお知らせ
- 11/12 15:30東京証券取引所スタンダード市場への市場区分変更申請に関するお知らせ
- 11/02 15:30第14回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ
- 10/30 15:30「Bondlido」の米国販売提携並びに上市時期について
- 10/01 15:30第三者割当てによる第14回新株予約権(行使価額修正条項付)及び第2回無担保社債の発行に係る払込完了に関するお知らせ
- 09/30 15:30「Bondlido」の米国販売提携並びに上市時期について
- 09/29 15:30第13回新株予約権の取得及び消却の完了並びに月間行使状況に関するお知らせ
- 09/14 15:45第13回新株予約権の取得・消却並びに第三者割当てによる第14回新株予約権(行使価額修正条項付)及び第2回無担保社債の発行に関するお知らせ
Filings from the past 12 months (9).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
No posts yet. Be the first to write something.
Write on the D.Western Therapeutics Institute, Inc. board
More Japanese stocks in English
- Daito Pharmaceutical Co.,Ltd.4577
- RaQualia Pharma Inc.4579
- Le Lien Co.,Ltd.457A
- SymBio Pharmaceuticals Limited4582
- Chiome Bioscience Inc.4583
- Kidswell Bio Corporation4584
- Medrx Co.,Ltd.4586
- PeptiDream Inc.4587
- Oncolys BioPharma Inc.4588
- PLAN DO Co.,Ltd.458A
- RIBOMIC Inc.4591
- SanBio Company Limited4592